Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714739 · ClinicalTrials.gov registry record · Phase 1
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
A Phase 1 study of CANCER,NOS, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 337
- Enrollment target
- 20
- Study locations
NCT01714739 is a Phase 1 study of CANCER,NOS that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 337 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT01714739, a Phase 1 study of CANCER,NOS, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 337 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination. In addition, to assess the combinations of lirilumab and nivolumab or lirilumab and nivolumab plus ipilimumab (BMS-734016) in subjects with advanced (metastatic and/or unresectable) refractory solid tumors.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Lirilumab
Study Locations (20)
Massachusetts
- Beth Israel Deaconess Med Ctr - Boston
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
- UPMC Eye and Ear Institute - Pittsburgh
Texas
- Texas Oncology-Central Austin Cancer Center - Austin
- University Of Texas Medical Branch Of Galveston - Galveston
Ontario
- Juravinski Cancer Center - Hamilton
- Princess Margaret Cancer Centre - Toronto
Other
- Local Institution - Bordeaux
- Local Institution - Lyon
California
- Ucsf - San Francisco
Florida
- Florida Cancer Affiliates - Ocala - Ocala
Illinois
- University Of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2012-10-07 |
| Est. Completion | 2019-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01714739
The ClinicalTrials.gov registry entry for NCT01714739 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 337 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CANCER,NOS appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT01714739 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT01714739 about?
NCT01714739 is a clinical study titled "A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors". To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination. In addition, to assess the combinations of l...
What is the current status of trial NCT01714739?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 337 participants. The study started on 2012-10-07. Estimated completion is 2019-12-13.
What conditions does trial NCT01714739 study?
This clinical trial studies the following conditions: CANCER,NOS.
What interventions are being tested in trial NCT01714739?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Lirilumab (DRUG).
Who is sponsoring clinical trial NCT01714739?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714739 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.